{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-21-000050","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.005592+00:00","generated_at":"2026-06-30T00:43:15.523227+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"West Pharma Q2 net sales $723.6M (+37.3%), EPS $2.47 (+104%); raises full-year guidance","bullets":["Net sales $723.6M, up 37.3% (organic +30.6%); reported diluted EPS $2.47, up 104%.","Adjusted diluted EPS $2.46, up 97%; Proprietary Products segment sales up 47%, driven by HVP components.","Raises FY2021 net sales guidance to $2.760-$2.785B (from $2.630-$2.655B) and adjusted EPS to $8.05-$8.20 (from $6.95-$7.10).","Strong demand from COVID-19 vaccines and base business; new capital spending tranche for HVP capacity expansion in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-21-000050","json":"https://secwatch.observer/filing/0000105770-21-000050.json","markdown":"https://secwatch.observer/filing/0000105770-21-000050.md","text":"https://secwatch.observer/filing/0000105770-21-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/0000105770-21-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/wst-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:43:15.523227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}